IP Library Granted Patent US 9,603,894
Granted Patent B2
US 9,603,894 · App. 13/883,005 · Granted Mar 28, 2017

Materials presenting notch signaling molecules to control cell behavior

Inventors: Lan Cao (Stoughton, MA); Kamal H. Bouhadir (Beirut, LB); David J. Mooney (Sudbury, MA)
Assignee: President and Fellows of Harvard College
A61K38/10A61K38/1709A61K47/4823A61K47/48246
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,603,894
App. No.
13/883,005
Granted
Mar 28, 2017
Kind
B2
Abstract

The invention provides a solution to the problem of delivering molecules in a physiologically relevant manner to direct cell fate. For example, a Notch ligand molecule is presented in a microenvironment that mimics the environment encountered in vivo. Accordingly, the invention features a cell delivery vehicle comprising a biocompatible hydrogel or polymer and a composition that binds to a Notch receptor and methods of directing cell fate, e.g., stem cell differentiation, using such compositions.

Claims (8)

1. A method of inducing differentiation of a population of mesenchymal stem cells comprising transiently contacting the population of mesenchymal stem cells with:

a) a biocompatible alginate hydrogel covalently linked to human Jagged-1, said Jagged-1 comprising the amino acid sequence of SEQ ID NO:1, or a fragment thereof, said fragment comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:3, and

b) a bone morphogenetic protein,

thereby inducing differentiation of the population of mesenchymal stem cells into a population of cells of osteogenic lineage, wherein the level of alkaline phosphatase activity of the population of cells after said contacting is increased by at least 4-fold as compared to the level of alkaline phosphatase activity of a population of mesenchymal stem cells that has been contacted with the bone morphogenetic protein but not the alginate hydrogel.

2. The method of claim 1 , wherein said bone morphogenetic protein is bone morphogenetic protein-4.

3. The method of claim 1 , wherein said population of cells of osteogenic lineage comprises bone cells or cartilage cells.

4. The method of claim 2 , wherein said bone morphogenetic protein-4 comprises amino acids 36-275 or 308-408 of SEQ ID NO:4.

5. The method of claim 1 , wherein said alginate hydrogel comprises alginate covalently linked to a peptide molecule comprising an arginine-glycine-aspartic acid (RGD) sequence.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 19, 2013
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030658/0086 →
Continuity (2)
Provisional Application 61411129 · Nov 8, 2010
Related Publication 20130331343A1 · Dec 12, 2013